Ignet

Gene Information

Gene symbol: MYO1G

Gene name: myosin IG

HGNC ID: 13880

Synonyms: HA-2

Related Genes

#	Gene Symbol	Number of hits
1	HLA-A	1 hits
2	HMHA1	1 hits
3	PRTN3	1 hits
4	XIAP	1 hits

Related Sentences

#	PMID	Sentence
1	15000488	The first clinical application of the hematopoietic minor histocompatibility antigens HA-1 and HA-2 is currently being explored in a stem cell-based setting for hematologic malignancies.
2	16707472	For minor histocompatibility antigens HA-1 and HA-2, normal cell expression is restricted to hemopoietic cells, and boosting the immune response to these antigens may potentiate graft-versus-leukemia effect without accompanying graft-versus-host disease.
3	16707472	To increase efficacy, expansion of HA-1- or HA-2-specific CTL before transplantation is desirable.
4	16707472	However, primary HA-1- or HA-2-specific CTL expanded in vitro are often of low avidity.
5	16707472	For clinical application, we constructed vaccines encoding HLA-A0201-restricted peptides from human HA-1 and HA-2, which were fused to DOM, and tested their performance in HLA-A0201-transgenic mice.
6	16707472	Strikingly, these mouse T cells efficiently killed human lymphoblastoid cell lines expressing endogenous HA-1 or HA-2.
7	16707472	High avidity is indicated by the independence of cytolysis from CD8/MHC class I interaction.
8	16707472	These safe epitope-specific vaccines offer a potential strategy to prime HA-1- or HA-2-specific CTL in transplant donors before adoptive transfer.
9	16707472	For minor histocompatibility antigens HA-1 and HA-2, normal cell expression is restricted to hemopoietic cells, and boosting the immune response to these antigens may potentiate graft-versus-leukemia effect without accompanying graft-versus-host disease.
10	16707472	To increase efficacy, expansion of HA-1- or HA-2-specific CTL before transplantation is desirable.
11	16707472	However, primary HA-1- or HA-2-specific CTL expanded in vitro are often of low avidity.
12	16707472	For clinical application, we constructed vaccines encoding HLA-A0201-restricted peptides from human HA-1 and HA-2, which were fused to DOM, and tested their performance in HLA-A0201-transgenic mice.
13	16707472	Strikingly, these mouse T cells efficiently killed human lymphoblastoid cell lines expressing endogenous HA-1 or HA-2.
14	16707472	High avidity is indicated by the independence of cytolysis from CD8/MHC class I interaction.
15	16707472	These safe epitope-specific vaccines offer a potential strategy to prime HA-1- or HA-2-specific CTL in transplant donors before adoptive transfer.
16	16707472	For minor histocompatibility antigens HA-1 and HA-2, normal cell expression is restricted to hemopoietic cells, and boosting the immune response to these antigens may potentiate graft-versus-leukemia effect without accompanying graft-versus-host disease.
17	16707472	To increase efficacy, expansion of HA-1- or HA-2-specific CTL before transplantation is desirable.
18	16707472	However, primary HA-1- or HA-2-specific CTL expanded in vitro are often of low avidity.
19	16707472	For clinical application, we constructed vaccines encoding HLA-A0201-restricted peptides from human HA-1 and HA-2, which were fused to DOM, and tested their performance in HLA-A0201-transgenic mice.
20	16707472	Strikingly, these mouse T cells efficiently killed human lymphoblastoid cell lines expressing endogenous HA-1 or HA-2.
21	16707472	High avidity is indicated by the independence of cytolysis from CD8/MHC class I interaction.
22	16707472	These safe epitope-specific vaccines offer a potential strategy to prime HA-1- or HA-2-specific CTL in transplant donors before adoptive transfer.
23	16707472	For minor histocompatibility antigens HA-1 and HA-2, normal cell expression is restricted to hemopoietic cells, and boosting the immune response to these antigens may potentiate graft-versus-leukemia effect without accompanying graft-versus-host disease.
24	16707472	To increase efficacy, expansion of HA-1- or HA-2-specific CTL before transplantation is desirable.
25	16707472	However, primary HA-1- or HA-2-specific CTL expanded in vitro are often of low avidity.
26	16707472	For clinical application, we constructed vaccines encoding HLA-A0201-restricted peptides from human HA-1 and HA-2, which were fused to DOM, and tested their performance in HLA-A0201-transgenic mice.
27	16707472	Strikingly, these mouse T cells efficiently killed human lymphoblastoid cell lines expressing endogenous HA-1 or HA-2.
28	16707472	High avidity is indicated by the independence of cytolysis from CD8/MHC class I interaction.
29	16707472	These safe epitope-specific vaccines offer a potential strategy to prime HA-1- or HA-2-specific CTL in transplant donors before adoptive transfer.
30	16707472	For minor histocompatibility antigens HA-1 and HA-2, normal cell expression is restricted to hemopoietic cells, and boosting the immune response to these antigens may potentiate graft-versus-leukemia effect without accompanying graft-versus-host disease.
31	16707472	To increase efficacy, expansion of HA-1- or HA-2-specific CTL before transplantation is desirable.
32	16707472	However, primary HA-1- or HA-2-specific CTL expanded in vitro are often of low avidity.
33	16707472	For clinical application, we constructed vaccines encoding HLA-A0201-restricted peptides from human HA-1 and HA-2, which were fused to DOM, and tested their performance in HLA-A0201-transgenic mice.
34	16707472	Strikingly, these mouse T cells efficiently killed human lymphoblastoid cell lines expressing endogenous HA-1 or HA-2.
35	16707472	High avidity is indicated by the independence of cytolysis from CD8/MHC class I interaction.
36	16707472	These safe epitope-specific vaccines offer a potential strategy to prime HA-1- or HA-2-specific CTL in transplant donors before adoptive transfer.
37	16707472	For minor histocompatibility antigens HA-1 and HA-2, normal cell expression is restricted to hemopoietic cells, and boosting the immune response to these antigens may potentiate graft-versus-leukemia effect without accompanying graft-versus-host disease.
38	16707472	To increase efficacy, expansion of HA-1- or HA-2-specific CTL before transplantation is desirable.
39	16707472	However, primary HA-1- or HA-2-specific CTL expanded in vitro are often of low avidity.
40	16707472	For clinical application, we constructed vaccines encoding HLA-A0201-restricted peptides from human HA-1 and HA-2, which were fused to DOM, and tested their performance in HLA-A0201-transgenic mice.
41	16707472	Strikingly, these mouse T cells efficiently killed human lymphoblastoid cell lines expressing endogenous HA-1 or HA-2.
42	16707472	High avidity is indicated by the independence of cytolysis from CD8/MHC class I interaction.
43	16707472	These safe epitope-specific vaccines offer a potential strategy to prime HA-1- or HA-2-specific CTL in transplant donors before adoptive transfer.
44	18790448	These strategies include the use of vaccines against minor histocompatibility antigens (HA-1, HA-2 and H-Y) and leukaemia-specific antigens (proteinase 3, Wilms' tumour 1 and BCR-ABL), and the adoptive transfer of leukaemia-specific T cells.
45	21406268	Passages of these viruses on Vero cells led to the appearance of single mutations in the HA(1) L194P or HA(2) G75R subunits that impaired virus stability.
46	24810638	Our culture protocol generated a clinically relevant number of mature CD1a myeloid DC and CD207 Langerhans cells (LC)-like DC subsets from CD34 HPC with >95% purity.
47	24810638	Additional studies revealed that UCC-DC and UCB-LC can efficiently expand minor histocompatibility antigen (MiHA) HA-1-specific cytotoxic T cells in the peripheral blood of leukemia patients and prime MiHA HA-1-specific and HA-2-specific cytotoxic T cells in vitro.